Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

LYEL stock hub

Lyell Immunopharma, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

LYELis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

451M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

LYEL

In the news

Latest news · LYEL

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-80.8

P25 -105.6P50 -46.5P75 -3.1

ROIC-32.8

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All LYEL market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

203

Groups with data

Currency

USD

Showing 203 of 203 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001806952
Company name	Lyell Immunopharma, Inc.
Country	United States
Country code	US
Cusip	55083R203
Employees	300
Employees Change	76%
Employees Change Percent	33.93
Enterprise value	$229.5M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2021-06-17
Isin	US55083R2031
Last refreshed	2026-05-10
Market cap	$451M
Market cap category	Small-Cap
Price	$19.33
Price currency	USD
Rev Per Employee	103.33x
Sector	Healthcare
Sic	2834
Symbol	LYEL
Website	https://www.lyell.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-54.63%
EV Sales Forward	12,785.63x
EV/Sales	7,404.12x
FCF yield	-29.8%
P/B ratio	1.5x
P/S ratio	14,548.96x
PS Forward	25,123.53x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	100%
Gross Profit	$31,000
Gross Profit Growth	-52.31%
Gross Profit Growth Q	-71.43%
Gross Profit Growth3 Y	-92.83%
Gross Profit Growth5 Y	-67.79%
Net Income	$-246.4M
Net Income Growth Quarters	5%
Net Income Growth Years	1%
Pretax Margin	-794,858.06%
Profit Per Employee	$-821,353
ROA	-29.66
Roa5y	-18.9
ROCE	-59.03
ROE	-80.76
Roe5y	-47.15
ROIC	-32.75

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	129.7%
Cagr3y	-26.95%
EPS Growth Quarters	5
EPS Growth Years	1
Revenue Growth	-52.31x
Revenue Growth Q	-71.43x
Revenue Growth Years	0x
Revenue Growth3 Y	-92.83x
Revenue Growth5 Y	-67.79x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0
Assets	$350.6M
Cash	$254M
Current Assets	$267.3M
Current Liabilities	$36.9M
Debt	$39.5M
Debt Equity	$0.14
Equity	$273.7M
Interest Coverage	-111
Liabilities	$77M
Long Term Assets	$83.3M
Long Term Liabilities	$40M
Net Cash	$221.5M
Net Cash By Market Cap	$49.11
Net Cash Growth	-18.88%
Net Debt Equity	$-0.81
Tangible Book Value	$273.7M
Tangible Book Value Per Share	$12.88
WACC	3.88

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	7.23
Net Working Capital	$-23.7M
Quick ratio	6.88
Working Capital	$230.4M
Working Capital Turnover	$0

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-38.93%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	129.57%
200-day SMA	20.18
3Y total return	-61.03%
50-day SMA	22.05
50-day SMA vs 200-day SMA	50over200
All Time High	396.8
All Time High Change	-95.13%
All Time High Date	2021-09-07
All Time Low	7.65
All Time Low Change	152.68%
All Time Low Date	2025-06-02
ATR	1.55
Beta	-0.06
Beta1y	1.96
Beta2y	1.59
Ch YTD	-37.2
High	20.51
High52	45
High52 Date	2025-12-22
High52ch	-57.04%
Low	19.14
Low52	7.65
Low52 Date	2025-06-02
Low52ch	152.68%
Ma50ch	-12.35%
Price vs 200-day SMA	-4.2%
RSI	37.61
RSI Monthly	40.16
RSI Weekly	45.7
Sharpe ratio	1.21x
Sortino ratio	2.48
Total Return	-38.93%
Tr YTD	-37.2
Tr1m	-11.25%
Tr1w	-7.2%
Tr3m	-14.88%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	5
Analyst Count Top	2
Analyst Price Target Top	$44.5
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-2.45
Earnings Revenue Estimate	4,400x
Earnings Revenue Estimate Growth	-37.14x
Operating Income	$-185.2M
Operating margin	-597,351.6
Price target	$30.6
Price Target Change	$58.3
Price Target Change Top	$130

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	10,388,060%
Float Percent	44.52%
Shares Insiders	8.12%
Shares Institutions	32.75%
Shares Out	23,332,524
Shares Qo Q	6.63%
Shares Yo Y	38.93%
Short Float	11.88%
Short Ratio	12.81
Short Shares	5.29

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-174.5M
Average Volume	74,604.2x
Bv Per Share	12.88
CAPEX	$-623,000
Ch1m	-11.25
Ch1w	-7.2
Ch1y	129.6
Ch3m	-14.88
Ch3y	-61.03
Ch6m	10.39
Change	-3.64%
Change From Open	-3.01
Close	20.06
Days Gap	-0.65
Depreciation Amortization	10,430,000
Dollar Volume	1,198,711.3
Earnings Date	2026-05-06
Earnings Time	amc
EBIT	$-185.2M
EBITDA	$-174.7M
EPS	$-13.06
F Score	1
FCF	$-134.4M
FCF EV Yield	-58.56x
FCF Per Share	$-5.76
Financing CF	102,127,000
Fiscal Year End	December
Founded	2,018
Investing CF	2,009,000
Ipr	13.71
Iprfo	-94.85
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-06
Last Report Date	2026-03-31
Last Split Date	2025-06-02
Last Split Type	Reverse
Last10k Filing Date	2026-03-12
Ma150	22.85
Ma150ch	-15.39%
Ma20	22.31
Ma20ch	-13.35%
Net CF	-29,660,000
Next Earnings Date	2026-08-11
Open	19.93
Optionable	Yes
Position In Range	13.87
Post Close	19.33
Postmarket Change Percent	-1.71
Postmarket Price	$19
Ppne	50,548,000
Price Date	2026-05-08
Ptbv Ratio	1.65
Relative Volume	0.83x
Revenue	31,000x
SBC By Revenue	129,354.84x
Share Based Comp	40,100,000
Tr6m	10.39%
Us State	California
Volume	62,013

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does LYEL pay a dividend?

Capital-return profile for this ticker.

Performance

LYEL stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns LYEL?

Insider, institutional, and short-interest positioning.

Institutional ownership

+32.7%

Float: +44.5% of shares outstanding

Insider ownership

+8.1%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

LYEL momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

37.6

Neutral momentum band

Price vs 200-day MA

-4.2%

50/200-day relationship not available

Beta (5Y)

-0.06

Less volatile than the market

Sharpe ratio

1.21

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About LYEL

Hub-level FAQ points readers to the deeper analysis pages.

What is the current LYEL stock rating?

Lyell Immunopharma, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full LYEL analysis?

The full report lives at /stocks/LYEL/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for LYEL?

The latest report frames LYEL around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the LYEL page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.